{"pub_date": "2016-04-03T00:00:00Z", "subsection_name": null, "lead_paragraph": "As investors look for the release of the drug maker\u2019s annual report, it has already found one error and warned of \u201cadditional accounting adjustments.\u201d", "print_page": "1", "document_type": "article", "byline": {"person": [{"rank": 1, "organization": "", "lastname": "MORGENSON", "firstname": "Gretchen", "role": "reported"}], "original": "By GRETCHEN MORGENSON"}, "multimedia": [{"width": 190, "height": 126, "url": "images/2016/04/03/business/gret1/gret1-thumbWide.jpg", "subtype": "wide", "legacy": {"wide": "images/2016/04/03/business/gret1/gret1-thumbWide.jpg", "widewidth": "190", "wideheight": "126"}, "type": "image"}, {"width": 600, "height": 400, "url": "images/2016/04/03/business/gret1/gret1-articleLarge.jpg", "subtype": "xlarge", "legacy": {"xlargewidth": "600", "xlargeheight": "400", "xlarge": "images/2016/04/03/business/gret1/gret1-articleLarge.jpg"}, "type": "image"}, {"width": 75, "height": 75, "url": "images/2016/04/03/business/gret1/gret1-thumbStandard.jpg", "subtype": "thumbnail", "legacy": {"thumbnail": "images/2016/04/03/business/gret1/gret1-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "type": "image"}], "section_name": "Business Day", "headline": {"content_kicker": "Fair Game", "print_headline": "Little Goof by Valeant May Grow", "main": "A Valeant Boo-Boo May Portend Bigger Errors", "kicker": "Fair Game"}, "source": "The New York Times", "blog": [], "word_count": "1052", "web_url": "http://www.nytimes.com/2016/04/03/business/a-valeant-boo-boo-may-portend-bigger-errors.html", "slideshow_credits": null, "news_desk": "SundayBusiness", "type_of_material": "News", "snippet": "As investors look for the release of the drug maker\u2019s annual report, it has already found one error and warned of \u201cadditional accounting adjustments.\u201d", "_id": "56fe800938f0d85faa67c733", "abstract": "Gretchen Morgenson Fair Game column speculates Valeant\u2019s $58 million accounting error may not be only one made by besieged pharmaceutical company; cites investment advisor Michael Krensavage, who points to two incidents in 2015 where firm may have inflated earnings and misled investors by pushing more than usual amount of products into distribution pipelines.", "keywords": [{"rank": "1", "name": "organizations", "value": "Valeant Pharmaceuticals International Inc", "is_major": "Y"}, {"rank": "3", "name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "N"}, {"rank": "4", "name": "subject", "value": "Securities and Commodities Violations", "is_major": "N"}, {"rank": "5", "name": "subject", "value": "Company Reports", "is_major": "N"}, {"rank": "6", "name": "subject", "value": "Accounting and Accountants", "is_major": "N"}]}